1 The Pattern of Signatures in Gastric Cancer Prognosis.

2 Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.

3 clinical utility of her2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer

4 tailoring dna vaccines: designing strategies against her2 positive cancers

5 the coexpression and prognostic significance of c-met, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study

6 immunohistochemical assessment of her2 expression in gastric cancer in a cohort of 118 brazilian patients

7 association between cln3 (neuronal ceroid lipofuscinosis, cln3 type) gene expression and clinical characteristics of breast cancer patients

8 liquid biopsy prevents inaccurate her2 status determination by in situ hybridization in a patient with invasive ductal adenocarcinoma of the breast: case report

9 structure based antibody-like peptidomimetics

10 improved aptamers for the diagnosis and potential treatment of her2-positive cancer

11 response to her2 inhibition in a patient with brain metastasis with egfr tki acquired resistance and an her2 amplification

12 omics and immunologic approaches to optimizing cure rates in her2-positive breast carcinomas.

13 pre-clinical assessment of 177lu-labeled trastuzumab targeting her2 for treatment and management of cancer patients with disseminated intraperitoneal disease

14 First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

15 Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis

16 Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

17 The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

18 Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.

19 Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.

20 Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample

21 The PI3K/AKT/mTOR and CDK4/6 pathways in endocrine resistant HR+/HER2- metastatic breast cancer: Biological mechanisms and new treatments

22 Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.

23 Dysregulated expression of repetitive DNA in ER+/HER2- breast cancer.

24 Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer.

25 Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer Enrolled in an Expanded Access Program

26 Reduction of Global H3K27me Enhances HER2/ErbB2 Targeted Therapy.

27 Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.

28 Seed-specific expression and analysis of recombinant anti-HER2 single-chain variable fragment (scFv-Fc) in Arabidopsis thaliana.

29 Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project

30 Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany

31 Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy

32 Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

33 What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?

34 Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.

35 AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer

36 Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab

37 Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.

38 Memenin Duktal Karsinoma in Situ Lezyonları: Histopatolojik özellikler ile p53, HER2/neu, bcl-2 ve PCNA Ekspresyonu arasındaki ilişki

39 Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: An Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.

40 Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study

41 the efficacy of the combination of eribulin and trastuzumab in advanced her2-positive breast cancer: the results of russian observational study

42 her2/neu and trastuzumab

43 loss of her2 positivity after trastuzumab in her2-positive gastric cancer: is change in her2 status significantly frequent?

44 preparasi fragmen gen dengan teknik allele-specific polymerase chain reaction (as-pcr) untuk standar marker snps human epidermal growth factor 2 (her2i655v) pada penderita kanker payudara

45 is the improved efficacy of trastuzumab and lapatinib combination worth the added toxicity? a discussion of current evidence, recommendations, and ethical issues regarding dual her2-targeted therapy

46 opisanie klinicheskikhsluchaev primeneniya kombinatsiys lapatinibom v lecheniiher2-pozitivnogo rasprostranennogoraka molochnoy zhelezy

47 efficacy of anti-her2 agents in combination with adjuvant or neoadjuvant chemotherapy for early and locally advanced her2-positive breast cancer patients: a network meta-analysis

48 association of her2 ecd and t-psa serum levels for possible breast cancer diagnosis

49 effect of vh–vl families in pertuzumab and trastuzumab recombinant production, her2 and fcγiia binding

50 clinical application of trastuzumab plus chemotherapy in the treatment of her2-positive gastric or gastro-oesophageal junction adenocarcinoma: a retrospective analysis of 75 cases

51 role of pertuzumab in the treatment of her2-positive breast cancer

52 anti-her3 domain 1 and 3 antibodies reduce tumor growth by hindering her2/her3 dimerization and akt-induced mdm2, xiap, and foxo1 phosphorylation

53 polymer–lipid hybrid anti-her2 nanoparticles for targeted salinomycin delivery to her2-positive breast cancer stem cells and cancer cells

54 emerging treatments for her2-positive early-stage breast cancer: focus on neratinib

55 blood genome-wide transcriptional profiles of her2 negative breast cancers patients

56 araguspongine c induces autophagic death in breast cancer cells through suppression of c-met and her2 receptor tyrosine kinase signaling

57 s. akÇa1,*, a. yu. konobeyev2, u. fischer2

58 Her2 V655 genotype and breast cancer progression in Korean women

59 Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience.

60 Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2- Metastatic Breast Cancer: A Podcast.

61 Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer.

62 Advances and challenges in targeted therapies for HER2-amplified colorectal cancer.

63 The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer.

64 Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Keyword Connections

Journals

Research Groups

Bibliographies